Megan Dillaman, PharmD, BCOP

Assistant Director with a proven track record of delivering high-quality oncology- and non-oncology-focused medical and value communication deliverables. Utilizes a detail-oriented approach to enhance efficiency and drive project success. Demonstrates strong organizational and multitasking abilities, coupled with effective problem-solving skills.

• Board Certified Oncology Pharmacist, Board of Pharmacy Specialties, 2015 to Present
• Registered Pharmacist, West Virginia, RP#0007906, 2012 to Present

• National Community Oncology Dispensing Association (NCODA)
• Hematology/Oncology Pharmacy Association (HOPA)

• Adjunct Faculty Member, West Virginia University School of Pharmacy, Morgantown, WV, 2015 to Present

• Best Practices: Survivorship Clinic, ASTCT Tandem Meetings, Orlando, FL, 2020
• Transforming the Treatment Paradigm in B-Cell Malignancies: Pharmacist Insights into BTK Inhibitors, HOPA Annual Meeting, Fort Worth, TX, 2019
• Pharmacist Impact on Improving Care across the Continuum, Premier Breakthroughs, Nashville, TN, 2018
• Preparative Regimens: Dosing Considerations in Special Populations, ASTCT Tandem Meetings, San Diego, CA, 2015
• Chemotherapy in Endometrial Cancer and Current Treatment Options, Annual Society of Gynecologic Oncology Allied Health Professionals Workshop, Nashville, TN, 2013

• Opportunities for product differentiation and evidence generation with a focus on health disparities information in the Academy of Managed Care Pharmacy Format for formulary submissions (AMCP Format) version 5.0., Pollack M, Cadarette S, Stewart F, Dillaman M, Abresch L, Crawford B, Jung J, Arregui M, Kanz Schroader B., 2024 AMCP Nexus Meeting
• Evaluation of screening and preventive care after implementation of a pharmacist-driven allogeneic hematopoietic cell transplant survivorship clinic., Smith A, Seago K, Yingling S, Dillaman M, Cumpston A., 2022 Vizient Pharmacy Network Meeting
• A review of current antineoplastic rounding practices at an outpatient cancer center., Malcolm S, Walker D, Seago K, Dillaman M, Ebbert B, Hill J., 56th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting
• Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic stem cell transplant recipients., Marciano K, Seago K, Dillaman M, Cumpston A., 17th Annual Hematology/Oncology Pharmacist Association Annual Conference
• Evaluation of an increased length of intravenous magnesium infusion on the need for magnesium replacement in patients after allogeneic stem cell transplant., Goodner J, Seago K, Dillaman M, Wen S, Cumpston A., 17th Annual Hematology/Oncology Pharmacist Association Annual Conference
• Evaluation of infusion-related reactions for weekly paclitaxel with low-dose intravenous dexamethasone., Hathaway E, Dillaman M, Hill J, Raymond A., 55th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting
• Retrospective review of rituximab utilization in the inpatient setting., Smith A, Dillaman M, Chiplinski A, Hill J., 55th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting
• Impact of body mass index (BMI) on plerixafor efficacy during hematopoietic progenitor cell (HPC) mobilization., Yingling SK, Gonzalez R, Dillaman M, Seago K, Kanate AS, Cumpston A., 16th Annual Hematology/Oncology Pharmacy Association Annual Conference, Tampa, FL
• Evaluation of flat-dose plerixafor versus weight-based plerixafor for stem cell mobilization., Banks C, Dent M, Hathaway E, Dillaman M, Cumpston A, Seago K., 16th Annual Hematology/Oncology Pharmacy Association Annual Conference, Tampa, FL
• Financial impact of outpatient rituximab administration prior to inpatient admission., Yingling SK, Cumpston A, Dillaman M., 54th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV
• Outpatient tacrolimus monitoring in allogeneic stem cell transplant recipients at an academic medical center., Marciano K, Seago K, Dillaman M., 54th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV
• Evaluation of adherence rates to aerosolized pentamidine for pneumocystis jiroveci pneumonia prophylaxis in hematopoietic cell transplant recipients., Murto K, Seago K, Dillaman M., 54th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV
• Comparison of bendamustine outcomes in smoking versus non-smoking patients undergoing treatment for chronic lymphocytic leukemia or non-Hodgkin lymphoma., Wight CE, Cumpston A, Chargualaf M, Win S, Kanate AS, Dillaman M., 15th Annual Hematology/Oncology Pharmacy Association Annual Conference, Fort Worth, TX
• Implementation and impact of a pharmacist-driven survivorship clinic after allogeneic hematopoietic cell transplantation., Seago K, Bodge M, Cumpston A, Veltri L, Kanate AS, Chargualaf M., 15th Annual Hematology/Oncology Pharmacy Association Annual Conference, Fort Worth, TX
• Evaluation of the transitions of care: Patients on oral oncolytics when admitted to the inpatient setting., Heffner C, Bodge M, Hill J., 15th Annual Hematology/Oncology Pharmacy Association Annual Conference, Fort Worth, TX
• Evaluation of survivorship screening and preventive care after allogeneic hematopoietic cell transplantation., Orton L, Seago K, Bodge M, Cumpston A, Chargualaf M., 15th Annual Hematology/Oncology Pharmacy Association Annual Conference, Fort Worth, TX
• Cost analysis and comparison of administering azacitidine in the inpatient versus outpatient settings., Wight CE, Bodge M, Cumpston A, Gizzi J, Muttillo D, Chargualaf M., 53rd Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Anaheim, CA
• Evaluation of the transitions of care: Patients on oral oncolytics when admitted to the inpatient setting., Heffner C, Bodge M, Hill J., 53rd Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Anaheim, CA
• Evaluation of thromboprophylaxis use in multiple myeloma patients receiving pomalidomide., Barthelmess E, Bodge M., 52nd Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Orlando, FL

• Analysis of spontaneous cytomegalovirus clearance after low level reactivation using a pre-emptive treatment threshold of 4,000 IU/mL in allogeneic hematopoietic cell transplant recipients., Walling M, Seago K, Dillaman M, Yingling S, Wen S, Veltri L, Ross KG, Cumpston A., J Infect Chemother., 2024-12-01, 30, 12, 1233-1236
• Evaluation of prolonged magnesium infusion after allogeneic hematopoietic cell transplant., Seago K, Goodner JA, Dillaman M, Wen S, Veltri L, Ross KG, Cumpston A., Support Care Cancer., 2023-12-22, 32, 1, 49, 10.1007/s00520-023-08257-6
• 30-day readmission reduction in a skilled facility population through pharmacist-driven medication reconciliation., Phillips M, Dillaman M, Matuga R, Sweet M, Lerfald N, Krupica T, Briggs F., J Healthc Qual., 2022-05-01, 44, 3, 152-160
• Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization., Yingling S, Gonzalez RM, Dillaman M, Seago K, Wen S, Ross KG, Veltri L, Cumpston A., Bone Marrow Transplant., 2022-04-25, 10.1038/s41409-022-01685-8
• Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplant recipients., Marciano KA, Seago K, Dillaman M, Ross KG, Veltri L, Cumpston A., Transplant Cell Ther., 2022-04-08, S2666-6367(22)01194-0, 10.1016/j.jtct.2022.03.028
• Toxicity assessment of concurrent gabapentin/pregabalin administration with high-dose melphalan in autologous hematopoietic cell transplant recipients., Angus J, Cumpston A, Veltri L, Ross KG, Wen S, Dillaman M., Support Care Cancer., 2021-12-01, 29, 12, 7925-7930
• Pharmacist-driven medication reconciliation reduces oral oncolytic medication errors during transitions-of-care., Heffner C, Dillaman M, Hill J., Am J Health Syst Pharm., 2020-11-16, 77, Supplement_4, S100-104
• Pharmacology of Drugs Used in Hematopoietic Cell Transplantation., Bodge M, Cumpston A., Hematopoietic Cell Transplantation for Malignant Conditions., Bashir Q, Hamadani M., 1st, St. Louis, Missouri, USA, Elsevier Health Sciences, 2019-01-01
• Geriatric assessments and medication therapy management approaches in elderly oncology patients., Glode AE, Bodge M, Culver ME., Consult Pharm., 2017-01-01, 32, Suppl B, 1-20
• Pre-transplant vaccinations in allogeneic stem cell transplantation donors and recipients: An often-missed opportunity for immunoprotection?, Harris AE, Styczynski J, Bodge M, Mohty M, Savani BN, Ljungman P., Bone Marrow Transplant., 2015-01-01, 50, 7, 899-903
• Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma., Bodiford A, Bodge M, Talbott MS, Reddy NM., OncoTargets and Therapy., 2014-01-01, 7, 1971-7
• Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: Analysis of the literature and recommendations., Bodge MN, Reddy S, Thompson MS, Savani BN., Biol Blood Marrow Transplant., 2014-01-01, 20, 7, 909-19
• Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic hepatic impairment: Analysis of the literature and recommendations., Bodge MN, Culos KA, Haider SN, Thompson MS, Savani BN., Biol Blood Marrow Transplant., 2014-01-01, 20, 5, 622-9
• Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: A prospective, observational study., Bodge M, Shillingburg A, Paul S, Biondo L., Pediatr Blood Cancer., 2014-01-01, 61, 6, 1111-3
• Erythematous rash following romiplostim administration in a patient with Autoimmune Lymphoproliferative Syndrome., Biondo L, Bodge M, Paul SR., Ann Pharmacother., 2013-01-01, 47, 1, e7